drugset / Trial / NCT06074562

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

NCT06074562

Phase 2 Completed 405 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.

Timeline

Start
2023-10-05
Primary completion
2025-06-11
Completion
2025-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3556050 Unknown Oral